$0.45 Earnings Per Share Expected for Phibro Animal Health (PAHC) This Quarter

Equities research analysts expect Phibro Animal Health (NASDAQ:PAHC) to announce earnings per share of $0.45 for the current quarter, Zacks reports. Zero analysts have made estimates for Phibro Animal Health’s earnings, with the highest EPS estimate coming in at $0.45 and the lowest estimate coming in at $0.44. Phibro Animal Health reported earnings per share of $0.39 in the same quarter last year, which would indicate a positive year-over-year growth rate of 15.4%. The business is expected to announce its next earnings results on Wednesday, August 29th.

On average, analysts expect that Phibro Animal Health will report full year earnings of $1.71 per share for the current fiscal year, with EPS estimates ranging from $1.70 to $1.73. For the next financial year, analysts forecast that the business will report earnings of $1.88 per share, with EPS estimates ranging from $1.86 to $1.90. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Phibro Animal Health.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Monday, May 7th. The company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.02. Phibro Animal Health had a net margin of 7.24% and a return on equity of 39.91%. The company had revenue of $209.00 million during the quarter, compared to the consensus estimate of $203.03 million. During the same quarter in the prior year, the firm posted $0.37 earnings per share. Phibro Animal Health’s revenue for the quarter was up 10.0% on a year-over-year basis.

PAHC has been the subject of several recent research reports. Credit Suisse Group increased their target price on shares of Phibro Animal Health from $39.00 to $42.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 9th. Zacks Investment Research downgraded shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a research note on Thursday, May 10th. Morgan Stanley increased their target price on shares of Phibro Animal Health from $30.00 to $36.00 and gave the stock an “underweight” rating in a research note on Wednesday, February 7th. BidaskClub downgraded shares of Phibro Animal Health from a “sell” rating to a “strong sell” rating in a research note on Friday, January 26th. Finally, ValuEngine upgraded shares of Phibro Animal Health from a “hold” rating to a “buy” rating in a research note on Wednesday, February 28th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $38.80.

NASDAQ PAHC opened at $44.80 on Tuesday. The company has a debt-to-equity ratio of 1.61, a current ratio of 3.17 and a quick ratio of 1.73. Phibro Animal Health has a 1 year low of $32.05 and a 1 year high of $46.00. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of 29.67, a P/E/G ratio of 2.67 and a beta of 0.92.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 27th. Investors of record on Wednesday, June 6th will be given a $0.10 dividend. The ex-dividend date is Tuesday, June 5th. This represents a $0.40 dividend on an annualized basis and a yield of 0.89%. Phibro Animal Health’s payout ratio is currently 26.49%.

In related news, VP Daniel M. Bendheim sold 3,960 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $40.06, for a total value of $158,637.60. Following the completion of the sale, the vice president now owns 3,860 shares in the company, valued at $154,631.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Bfi Co., Llc sold 9,930 shares of the firm’s stock in a transaction dated Friday, May 18th. The shares were sold at an average price of $45.05, for a total transaction of $447,346.50. Following the completion of the sale, the insider now owns 2,070 shares of the company’s stock, valued at approximately $93,253.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 189,628 shares of company stock valued at $7,482,221. 51.88% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in PAHC. First Manhattan Co. acquired a new stake in Phibro Animal Health in the fourth quarter valued at about $100,000. Royal Bank of Canada lifted its position in Phibro Animal Health by 2,104.6% in the first quarter. Royal Bank of Canada now owns 3,814 shares of the company’s stock valued at $151,000 after purchasing an additional 3,641 shares during the period. Dean Capital Investments Management LLC acquired a new stake in Phibro Animal Health in the fourth quarter valued at about $200,000. Highbridge Capital Management LLC acquired a new stake in Phibro Animal Health in the first quarter valued at about $214,000. Finally, Piermont Capital Management Inc. acquired a new stake in Phibro Animal Health in the first quarter valued at about $223,000. Hedge funds and other institutional investors own 48.83% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.

Get a free copy of the Zacks research report on Phibro Animal Health (PAHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Phibro Animal Health (NASDAQ:PAHC)

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply